Japan Biotechno Pharma

What Japan Biotechno Pharma does

Japan Biotechno Pharma Co., Ltd. (日本バイオテクノファーマ株式会社) is a privately-held Japanese pharmaceutical and medical device company headquartered in Chuo-ku, Tokyo, operating with 11–50 employees across three integrated business lines: pharmaceutical products (including Tepoxxx Capsule 200mg/Tecovirimat — Japan's first approved treatment for smallpox, mpox, cowpox, and vaccinia complications — alongside antibody drugs and vaccines/globulins); medical devices and consumer health products (surgical instruments, infection-prevention eyewear such as Shield Frame, the WellisAir air purification system validated against influenza A H3N2, and face shields); and in vitro diagnostics plus animal health (J-Bio Rapid PCR Kit SARS-CoV-2, COVID-19 antibody/antigen kits, iSWAB Microbiome EL specimen tubes, the WITHaPET AI digital stethoscope, and the PIPPO pet urine test kit). The company holds Class 1 pharmaceutical manufacturing/sales, Class 1 medical device, in vitro diagnostic, and advanced medical device sales permits issued by Japanese regulators between 2017 and 2020, and has received AMED grants for emerging/re-emerging infectious disease drug development in consecutive fiscal years. Revenue is generated through a hybrid model: direct B2B sales of pharmaceuticals, IVDs, and medical devices to healthcare institutions; a multi-brand direct-to-consumer e-commerce footprint via the Well-Being OnlineShop and sub-brand storefronts (WellisAir, WithaPet, Pippo); and physical distribution through its newly established Korea (August 2024) and Vietnam (May 2025) branches, primarily serving healthcare professionals, medical institutions, veterinary clinics, pet owners, and consumer wellness buyers across Japan, South Korea, and Vietnam.

Name

Japan Biotechno Pharma

Legal name

日本バイオテクノファーマ株式会社 (Japan Biotechno Pharma Co., Ltd.)

Website

https://japanbiotechnopharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Japan Biotechno Pharma is a Tokyo-based pharmaceutical and medical device company manufacturing antivirals, in vitro diagnostics, and animal health products, serving healthcare institutions, veterinary clinics, and consumers across Japan, Korea, and Vietnam.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Medical Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF)

Keywords

• Pharmaceutical manufacturing
• Biopharmaceutical development
• Medical device manufacturing
• In vitro diagnostics
• Veterinary medical devices

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Revenue from antiviral drugs, antibody pharmaceuticals, vaccines/globulins, and approved treatments including Tepoxxx Capsule for poxviruses
2. Medical Devices: Surgical instruments, infection prevention glasses (face shields), and related medical equipment
3. In Vitro Diagnostics: J-Bio rapid PCR kits and other diagnostic pharmaceutical products
4. Animal Health Products: AI digital stethoscopes, pet urine test kits, and animal health monitoring devices
5. Well-Being Consumer Products: WellisAir air purification systems and consumer wellness products sold through online shop

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Japan Biotechno Pharma manufactures and distributes pharmaceutical products (antiviral drugs including Japan's first approved Tecovirimat treatment for poxvirus complications, antibody drugs, vaccines, and globulins), medical devices (surgical instruments, infection protection eyewear, face shields, and the WellisAir air purification system), in vitro diagnostics (J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits), and animal health products (AI-powered digital stethoscope and pet urine test kits). The company serves medical professionals, healthcare institutions, veterinary clinics, and individual consumers through its own e-commerce storefront and direct sales.

Product overview

Japan Biotechno Pharma operates as a diversified pharmaceutical and medical technology company with three main business segments: (1) Pharmaceutical Business covering antiviral drugs (Tepoxxx Capsule 200mg/Tecovirimat - Japan's first treatment for poxvirus complications), antibody drugs, and vaccines/globulins; (2) Medical Device Business including surgical instruments, infection control products (Shield Frame glasses, face shields), and WellisAir air purification system proven effective against influenza A virus and coronavirus; and (3) In Vitro Diagnostics and Animal Health Products including J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits, iSWAB microbiome specimen collection tubes, AI-powered WITHaPET digital stethoscope, and PIPPO pet urine test kit. The portfolio spans human and veterinary applications with both pharmaceutical and medical device products.

Differentiator

Problem solved

Functional benefit

Brands

• WellisAir: Air purification system for sterilization and air quality improvement.
• J-Bio
• WITHaPET
• PIPPO
• Tepox

Products and services

• Tepoxxx Capsule 200mg (Tecovirimat) Antiviral capsule drug containing Tecovirimat 200mg, indicated for treatment of poxvirus infections including smallpox, mpox, cowpox, and post-vaccination complications. Approved as Japan's first such treatment for healthcare professionals and medical institutions.
• WellisAir Air Purification System Air sterilization and purification device confirmed to reduce infectivity of influenza A virus (H3N2) and coronavirus. Sold to consumers and businesses seeking infection prevention through air quality control.
• WITHaPET Digital Stethoscope AI-powered digital stethoscope designed for veterinary professionals and pet owners to monitor pet health through digital auscultation.
• PIPPO Pet Urine Test Kit At-home urine testing kit for pets, enabling pet owners to perform preliminary health screening for their animals.
• J-Bio Rapid PCR Kit SARS-CoV-2 In vitro diagnostic reagent enabling rapid PCR detection of SARS-CoV-2 for clinical laboratories and healthcare facilities, with regulatory approval (approval number 30300EZX00073000).
• COVID-19 Antibody Test Kit (IgM/IgG) Rapid detection test kit for IgM and IgG antibodies to SARS-CoV-2, designed for healthcare professionals and diagnostic use to assess immune response following infection.
• COVID-19 Antigen Test Kit Antigen detection test kit for identifying active SARS-CoV-2 infection, validated for the Omicron variant, sold as 2-test individual packaging.
• Shield Frame Infection Protection Glasses Droplet protection eyewear developed for medical professionals to prevent infection during clinical work.
• Face Shield Japanese-made face shield for droplet prevention, emphasizing comfort and performance for infection control in medical and workplace settings.
• iSWAB Microbiome EL Specimen collection and transport tube enabling RNA extraction in 5 minutes for microbiome analysis, used by research and clinical laboratories.
• Antibody Drugs Biopharmaceutical antibody drugs for therapeutic applications, developed and distributed for healthcare institutions.
• Vaccines and Globulins Vaccine and immunoglobulin (globulin) products for immunization and passive immunity, distributed to medical institutions and healthcare providers.
• Surgical Instruments and Equipment Medical devices and surgical instruments for healthcare facilities, distributed under the company's Class 1 medical device manufacturing and sales license.

Quantifiable outcome

• Japan's first approved poxvirus treatment (Tepoxxx Capsule 200mg) - approved January 7, 2025
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Japan Agency for Medical Research and Development (AMED)coreStrategic or Co-development Partner · 1 February 2021Japan Biotechno Pharma was selected for AMED's programs for emerging and re-emerging infectious disease drug development in both Reiwa 3 (2021) and Reiwa 4 (2022) fiscal years, receiving government support for innovative pharmaceutical development targeting infectious diseases.

Scale indicators3 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Chimerix: Chimerix develops antivirals targeting poxviruses and other infectious diseases. Comparable to Japan Biotechno Pharma as a small-cap antiviral developer with regulatory expertise in the same disease space as Tepoxxx.
• Bavarian Nordic: Bavarian Nordic develops vaccines and therapeutics against poxviruses including mpox/smallpox (JYNNEOS vaccine). Comparable as a player in the broader poxvirus preparedness ecosystem, often used alongside Tecovirimat treatment.
• SIGA Technologies: SIGA Technologies is the originator of Tecovirimat (TPOXX), the same active ingredient Japan Biotechno Pharma now sells in Japan under the Tepoxxx brand. Both companies operate in the poxvirus antiviral space and pursue government stockpiling channels.

Broad incumbents

• FUJIFILM Holdings: FUJIFILM's healthcare segment includes pharmaceuticals, medical devices, and IVD reagents. Comparable as a diversified Japanese healthcare conglomerate with overlapping product categories across therapeutics, devices, and diagnostics.
• Denka Company Limited: Denka is a Japanese chemical and specialty manufacturer with a healthcare segment that includes in vitro diagnostics and infection prevention products. Comparable as a Japanese company with overlapping diagnostic and medical device offerings.
• H.U. Group Holdings (formerly SRL): H.U. Group operates clinical laboratory testing services and IVD products in Japan. Comparable as a Japanese diagnostics player with relevant IVD distribution and laboratory services overlap.
• Sysmex Corporation: Sysmex is a leading Japanese in vitro diagnostics company with global reach. Comparable as a Japan-based IVD player, though much larger; useful for IVD regulatory and commercial benchmarking relevant to J-Bio PCR Kit.
• Shionogi & Co., Ltd. Shionogi is a Japanese pharmaceutical company with a strong infectious disease and antiviral portfolio (including COVID-19 therapeutics). Comparable as a Japan-based pharma with regulatory expertise and government relationships in infectious disease drug development.
• KM Biologics: KM Biologics is a Japanese vaccine and biologics manufacturer owned by Meiji Holdings. Comparable as a domestic Japanese player with biopharmaceutical manufacturing capabilities, vaccine portfolio, and regulatory licenses aligned with Japan Biotechno Pharma's pharmaceutical business.

Emerging players

• AnGes MG: AnGes is a Japanese biotech focused on DNA vaccines and genetic medicines, with COVID-19 vaccine development history. Comparable as a small-cap Japanese biopharmaceutical with infectious disease R&D focus and government grant funding experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Japan Biotechno Pharma